Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | BLM | P54132 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019669 | 0.78 | — | — | |
| SCHEMBL22017051 | 0.77 | TAAR1 (0.33) | TAAR1 | |
| SCHEMBL10807348 | 0.74 | AOC3 (0.33) | TSHRLMNA | |
| SCHEMBL6363021 | 0.74 | — | — | |
| SCHEMBL5694337 | 0.72 | CSNK1E (0.38) | KDM4EALDH1A1ADRB2GAA | |
| SCHEMBL5756561 | 0.71 | KDM5A (0.33) | HIF1AKDM4EALDH1A1ADRA2AADRA2C | |
| SCHEMBL5960607 | 0.70 | — | — | |
| SCHEMBL5698996 | 0.70 | — | — | |
| SCHEMBL4409393 | 0.69 | — | — | |
| SCHEMBL10366551 | 0.69 | DAO (0.37) | KDM4ETSHRGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049245-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2005-03-03 | — | — | US | disclosed |
| WO-2004106345-A2 | HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049245-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | RPL35, ZC3HAV1, RPL5 | HIF1A 2960/4885KDM4E 775/4885BLM 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.